This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Leukemia & Lymphoma Society Awards $1.68 Million To Improve Outcomes For Patients With Acute Promyelocytic Leukemia

WHITE PLAINS, N.Y., Jan. 25, 2013 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) has awarded Anand Jillella, M.D., Chief of Hematology, Oncology and Bone Marrow Transplant at the Georgia Regents University in Augusta, GA, with $1.68 million in funding from LLS's Therapy Acceleration Program (TAP). Dr. Jillella's proposal entitled "A Simple Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL)" will be funded over the next five years.

The goal of this project is to reduce the mortality rate in the induction therapy period by educating community oncologists and hematologists with a simple and straightforward treatment algorithm for the care of newly diagnosed patients with APL, a rare subtype of acute myeloid leukemia that affects marrow cells called promyelocytes. The results of the program will be documented as part of a patient registry in APL.

The funding of Dr. Jillella's project is in line with LLS's strategic initiative, which is to speed the development of blood cancer drugs, treatments and supportive diagnostics that have the potential for high impact on the current treatment outcomes for patients with blood cancer, especially in areas of high unmet medical need.

"LLS is eager to support this research project in the hopes that it will lead to a greater understanding of optimal treatment for this rare form of leukemia, and ultimately, improved outcomes for patients with APL especially those that live relatively far from major academic centers," said Richard Winneker, LLS senior vice president of research.

For more on LLS's Therapy Acceleration Program, please visit

About The Leukemia & Lymphoma SocietyThe Leukemia & Lymphoma Society ® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.  

Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit or contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.

Contact: Andrea Greif 914-821-8958

SOURCE The Leukemia & Lymphoma Society

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.46 -1.40%
GOOG $689.89 -0.16%
FB $116.17 -0.48%
TSLA $240.84 -2.80%
YHOO $36.33 -0.71%


Chart of I:DJI
DOW 17,691.74 -139.02 -0.78%
S&P 500 2,054.89 -20.92 -1.01%
NASDAQ 4,749.08 -56.2110 -1.17%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs